

PRODUCT INFORMATION



FTase Inhibitor II (trifluoroacetate salt)

Item No. 16607

Formal Name: N-[4-[[[(2R)-2-amino-3-mercapto-1-oxopropyl]amino]benzoyl]-L-methionine, trifluoroacetate salt

Synonyms: Farnesyltransferase Inhibitor II, FTI-II

MF: C₁₅H₂₁N₃O₄S₂ • XCF₃COOH

FW: 371.5


Purity: ≥80%

UV/Vis.: λ_{max}: 211, 268 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

FTase inhibitor II (trifluoroacetate salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the FTase inhibitor II (trifluoroacetate salt) in water. The solubility of FTase inhibitor II (trifluoroacetate salt) in water is approximately 25 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Farnesylation involves the utilization of farnesyl pyrophosphate (FPP), an intermediate in the mevalonate pathway, by farnesyltransferase (FTase) to add a lipid, farnesyl, to certain proteins.^{1,2} This post-translational modification is crucial in allowing target proteins, including Ras, to associate with, and function at, membranes. FTase Inhibitor II is a cell-permeable analog of FPP that potently inhibits FTase (IC₅₀ = 50-75 nM), preventing farnesylation of Ras.³ It does not inhibit geranylgeranyl transferase at similar concentrations (IC₅₀ > 100 μM).³ FTase Inhibitor II displays no toxicity to untransformed cells but blocks Ras-mediated transformation of NIH 3T3 cells.³

References

- Berndt, N., Hamilton, A.D., and Sebt, S.M. Targeting protein prenylation for cancer therapy. *Nat. Rev. Cancer* **11**(11), 775-791 (2011).
- Appels, N.M.G.M., Beijnen, J.H., and Schellens, J.H.M. Development of farnesyl transferase inhibitors: A review. *Oncologist* **10**(8), 565-578 (2005).
- Manne, V., Ricca, C.S., Brown, J.G., et al. Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. *Drug Dev. Res.* **34**(2), 121-137 (1995).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM